docetaxel
E261833
Docetaxel is a chemotherapy drug in the taxane class used to treat various cancers, including breast, lung, prostate, and gastric cancers, by inhibiting cell division.
All labels observed (1)
| Label | Occurrences |
|---|---|
| docetaxel canonical | 3 |
How this entity was disambiguated
This entity first appeared as the object of triple T2371116 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: docetaxel Context triple: [Perjeta, usedInCombinationWith, docetaxel]
-
A.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
B.
Xeloda
Xeloda is an oral chemotherapy drug (capecitabine) commonly used to treat various cancers, including colorectal and breast cancer.
-
C.
Avastin
Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
-
D.
bortezomib
Bortezomib is a proteasome inhibitor chemotherapy drug primarily used in the treatment of multiple myeloma and certain types of lymphoma.
-
E.
Herceptin
Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: docetaxel Target entity description: Docetaxel is a chemotherapy drug in the taxane class used to treat various cancers, including breast, lung, prostate, and gastric cancers, by inhibiting cell division.
-
A.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
B.
Xeloda
Xeloda is an oral chemotherapy drug (capecitabine) commonly used to treat various cancers, including colorectal and breast cancer.
-
C.
Avastin
Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
-
D.
bortezomib
Bortezomib is a proteasome inhibitor chemotherapy drug primarily used in the treatment of multiple myeloma and certain types of lymphoma.
-
E.
Herceptin
Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
- F. None of above. chosen
Statements (54)
| Predicate | Object |
|---|---|
| instanceOf |
antineoplastic agent
ⓘ
chemotherapy drug ⓘ mitotic inhibitor ⓘ taxane ⓘ |
| ATCCode | L01CD02 ⓘ |
| belongsToClass | taxoids ⓘ |
| bioavailability | 100% (intravenous) ⓘ |
| chemicalFormula | C43H53NO14 ⓘ |
| commonAdverseEffect |
alopecia
ⓘ
anemia ⓘ fluid retention ⓘ mucositis ⓘ nausea ⓘ neutropenia ⓘ peripheral neuropathy ⓘ |
| contraindication |
baseline neutrophil count <1500/mm3
ⓘ
severe hepatic impairment ⓘ |
| derivedFrom | 10-deacetylbaccatin III ⓘ |
| developedBy | Rhône-Poulenc Rorer ⓘ |
| eliminationHalfLife | 11 hours ⓘ |
| excretion |
bile
ⓘ
feces ⓘ |
| firstApprovedBy |
Food and Drug Administration
ⓘ
surface form:
U.S. Food and Drug Administration
|
| hasIUPACName | (2R,3S)-N-carboxy-3-phenylisoserine N-tert-butyl ester, 13-ester with 5β,20-epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4-acetate 2-benzoate ⓘ |
| hasMolarMass | 807.88 g/mol ⓘ |
| indication |
breast cancer
ⓘ
gastric cancer ⓘ head and neck cancer ⓘ non-small cell lung cancer ⓘ ovarian cancer ⓘ prostate cancer ⓘ |
| legalStatus | prescription-only ⓘ |
| mechanismOfAction |
inhibits cell division in the M phase of the cell cycle
ⓘ
inhibits depolymerization of microtubules ⓘ stabilizes microtubules ⓘ |
| metabolism | hepatic ⓘ |
| oftenUsedInCombinationWith |
cisplatin
ⓘ
cyclophosphamide ⓘ doxorubicin ⓘ prednisone ⓘ |
| origin | semi-synthetic derivative of paclitaxel ⓘ |
| pregnancyCategory | D (US) ⓘ |
| primaryMetabolismEnzyme |
CYP3A4
ⓘ
CYP3A5 ⓘ |
| proteinBinding | >94% ⓘ |
| requiresPremedicationWith | corticosteroids ⓘ |
| routeOfAdministration | intravenous ⓘ |
| seriousAdverseEffect |
febrile neutropenia
ⓘ
severe hypersensitivity reactions ⓘ |
| sourcePlant |
Taxus
ⓘ
surface form:
European yew (Taxus baccata)
|
| targets | tubulin ⓘ |
| tradeName |
Docefrez
ⓘ
Taxotere ⓘ |
| yearOfFirstApproval | 1996 ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: docetaxel Description of subject: Docetaxel is a chemotherapy drug in the taxane class used to treat various cancers, including breast, lung, prostate, and gastric cancers, by inhibiting cell division.
Referenced by (3)
Full triples — surface form annotated when it differs from this entity's canonical label.